Direct Fibroblast Conversion to Proliferative Neural Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for converting human fibroblasts into neural stem cells face challenges such as lengthy differentiation periods, low efficiency, and genetic instability, particularly when using viral systems for gene insertion, which can lead to tumorigenesis and other side effects.
Innovation Solution
A method utilizing a combination of Sendai virus, mRNA or miRNA, and specific small molecule compounds like thiazovivin, valproic acid, purmorphamine, A8301, SB43154, CHIR99021, 5-aza-2′-deoxycytidine, and DZNep to directly differentiate fibroblasts into neural stem cells, avoiding gene insertion and enhancing efficiency and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral systems are used to form neural stem cells from fibroblasts, then differentiation efficiency is improved, but genetic stability deteriorates due to random insertion of genes causing mutations
Solution Approach 1:
The patent extracts and removes the viral vector component from the differentiation process. Instead of using viral systems to deliver transcription factors, the invention uses direct transfection methods (lipofection, electroporation) to introduce plasmids containing transcription factor genes (Oct4, Sox2, Klf4, c-Myc) into fibroblasts, thereby eliminating the genetic instability caused by viral random insertion while maintaining differentiation efficiency
Solution Approach 2:
The patent introduces plasmids as an intermediary carrier to deliver transcription factor genes into fibroblasts. These plasmids serve as temporary vectors that can be introduced via non-viral methods (lipofection, electroporation) and do not integrate into the host genome, thus mediating the transfer of reprogramming genes without causing genetic instability
2Quantity of substance
If undifferentiated embryonic stem cells or induced pluripotent stem cells are transplanted, then cell availability is improved, but tumorigenesis risk increases due to teratoma formation
Solution Approach 1:
The patent performs preliminary differentiation of fibroblasts into neural stem cells before transplantation. By directly converting fibroblasts into neural stem cells (rather than using undifferentiated pluripotent stem cells), the invention ensures that cells are already committed to a specific lineage, thereby preventing teratoma formation while maintaining adequate cell availability for transplantation
Solution Approach 2:
The patent converts the limitation of fibroblasts (being differentiated somatic cells with limited therapeutic potential) into a benefit by directly reprogramming them into neural stem cells. This approach transforms what was previously a disadvantage (differentiated state) into an advantage (direct lineage commitment preventing tumorigenesis while providing sufficient cell numbers)
3Adaptability or versatility
If direct cross-differentiation is used to convert fibroblasts into neurons, then therapeutic application potential is improved, but cell quantity deteriorates because differentiated neurons cannot proliferate sufficiently
Solution Approach 1:
The patent segments the differentiation process into two distinct stages: first, conversion of fibroblasts into neural stem cells (which can proliferate), and second, differentiation of neural stem cells into neurons (which provide therapeutic benefit). This segmentation allows sufficient cell expansion at the neural stem cell stage before terminal differentiation, resolving the contradiction between cell quantity and therapeutic potential
Data Source
AI summary
The present invention relates to a method of converting human fibroblasts into neural stem cells, and more particularly, to a conversion method through direct cross-differentiation of human fibroblasts into neural stem cells using a combination of Sendai virus, mRNA or miRNA of a stem cell-related factor, and a small molecule compound, and a use thereof. According to the present invention, since high-quality neural stem cells may be induced from human fibroblasts through direct cross-differentiation within a short period of time, it is possible to secure a sufficient amount of cells for cell therapy, and since there is no side effect of tumorigenesis, the present invention may be used as a cell therapeutic agent for brain diseases.